CRO ShangPharma is considering an offer from private equity firm TPG Star Charisma to buy up the Chinese company's outstanding shares. ShangPharma has brought in JP Morgan for consulting, and the company is valued at up to $176 million, according to Outsourcing-Pharma. Among the CRO's clients are Eli Lilly ($LLY) and GlaxoSmithKline ($GSK). Report